Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase

Volker Rudolph, Tanja K. Rudolph, Francisco J. Schopfer, Gustavo Bonacci, Denise Lau, Katalin Szöcs, Anna Klinke, Thomas Meinertz, Bruce A. Freeman and Stephan Baldus
Journal of Pharmacology and Experimental Therapeutics November 2008, 327 (2) 324-331; DOI: https://doi.org/10.1124/jpet.108.142414
Volker Rudolph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanja K. Rudolph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco J. Schopfer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gustavo Bonacci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Lau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katalin Szöcs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Klinke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Meinertz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce A. Freeman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Baldus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Bivalirudin, a direct thrombin inhibitor, has emerged as an important alternative to heparin in patients undergoing percutaneous coronary intervention. However, it remains elusive if potentially adverse extracoagulant properties are responsible for the fact that its favorable effects in clinical studies are mainly driven by a reduction in bleeding events. The aim of the current study was to determine the effects and mechanisms of acute treatment with bivalirudin in comparison to heparin on NO bioavailability, an important factor for the pathogenesis of ischemic events. In particular, we studied the interaction between bivalirudin and myeloperoxidase (MPO), a leukocyte-derived enzyme that consumes endothelial-derived nitric oxide (NO), modifies a variety of biological targets, and thus affects the integrity of the vessel wall. In patients undergoing elective percutaneous coronary intervention, bivalirudin, in contrast to heparin, exhibited a significant decrease in plasma MPO levels (p = 0.03) accompanied by a deterioration of flow-mediated dilation (p = 0.02), a surrogate for endothelial NO bioavailability. In vitro experiments revealed avid binding of bivalirudin to both bovine aortic endothelial cells (BAEC) and MPO. Methylation of bivalirudin carboxyl groups at the carboxyl-terminal end revealed the specific binding site of bivalirudin to MPO. Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications. These results illustrate dichotomous extracoagulant properties of heparins and thrombin inhibitors and suggest that bivalirudin acutely impairs endothelial NO bioavailability, thereby underscoring the potentially critical role of MPO as a mediator of vascular function.

Footnotes

  • This work was supported by Deutsche Forschungsgemeinschaft Grants Ba 1870/3 (to S.B.) and Ru 1472/1-1 (to T.R.), Deutsche Herzstiftung (to S.B. and V.R.), and National Institutes of Health Grants HL58115 and HL 64937 (to B.F.).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.108.142414.

  • ABBREVIATIONS: MPO, myeloperoxidase; BAEC, bovine aortic endothelial cells; ESI-LC-MS, electrospray ionization liquid chromatography mass spectrometry; FMD, flow-mediated dilation; ANOVA, analysis of variant; IR, interquartile range; NO, nitric oxide, TMB, tetramethylbenzidine.

  • ↵ Embedded Image The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

    • Received June 16, 2008.
    • Accepted August 12, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 3
1 Dec 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase

Volker Rudolph, Tanja K. Rudolph, Francisco J. Schopfer, Gustavo Bonacci, Denise Lau, Katalin Szöcs, Anna Klinke, Thomas Meinertz, Bruce A. Freeman and Stephan Baldus
Journal of Pharmacology and Experimental Therapeutics November 1, 2008, 327 (2) 324-331; DOI: https://doi.org/10.1124/jpet.108.142414

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase

Volker Rudolph, Tanja K. Rudolph, Francisco J. Schopfer, Gustavo Bonacci, Denise Lau, Katalin Szöcs, Anna Klinke, Thomas Meinertz, Bruce A. Freeman and Stephan Baldus
Journal of Pharmacology and Experimental Therapeutics November 1, 2008, 327 (2) 324-331; DOI: https://doi.org/10.1124/jpet.108.142414
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HFpEF, Obesity and Hypertension
  • Controlled LDL Cholesterol reduces CV events
  • Compression no-reflow in intestinal ischemia-reperfusion
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics